——– Click Ther­a­peu­tics™ Reports Pre­lim­i­nary Results of a 416-Par­tic­i­pant Clin­i­cal Study Demon­strat­ing Excep­tion­al Engage­ment and Effi­ca­cy of Click­o­tine®, a Patent-Pend­ing Dig­i­tal Ther­a­peu­tics™ Pro­gram for Smok­ing Ces­sa­tion (press release): “Click Ther­a­peu­tics, Inc. (“Click”), a com­pa­ny devel­op­ing a suite of per­son­al­ized data-dri­ven dig­i­tal ther­a­peu­tics for chron­ic health con­di­tions, announces today pre­lim­i­nary results of its ful­ly remote clin­i­cal…